The cannabis industry is experiencing a historic shift that could reshape how we understand and access this plant medicine. On December 18, 2025, President Trump signed an executive order directing federal authorities to expedite the process of reclassifying marijuana from a Schedule I to a Schedule III controlled substance. For cannabis consumers in Washington state and patients at your trusted Tacoma dispensary, understanding these changes is essential to navigating the evolving landscape of legal cannabis.
Disclaimer: This article is for educational and informational purposes only. The information provided does not constitute medical advice, and Mary Mart does not claim that cannabis treats, cures, or prevents any medical condition. Cannabis and CBD products have not been evaluated or approved by the FDA. Always consult with a qualified healthcare professional before using cannabis products, especially if you have underlying health conditions or are taking medications.
Understanding the Current Federal Classification System
Before diving into what’s changing, it’s important to understand how the federal government currently classifies controlled substances. The Drug Enforcement Administration (DEA) organizes drugs into five schedules based on their potential for abuse and accepted medical use.
Schedule I substances are defined as having no accepted medical use and high abuse potential, while Schedule III substances have moderate to low potential for physical and psychological dependence. Currently, cannabis sits alongside heroin and LSD in Schedule I, despite being legal for medical or recreational use in most states, including Washington.
What Does Schedule III Mean?
Schedule III drugs include medications like products with less than 90 milligrams of codeine per dosage unit, ketamine, anabolic steroids, and testosterone. These substances are recognized as having legitimate medical applications while carrying a lower risk profile than Schedule I or II drugs. Moving cannabis to Schedule III would mark the first time in nearly a century that federal law acknowledges marijuana’s medical value.
The Path to Rescheduling: A Timeline
The journey toward cannabis rescheduling has been years in the making. In October 2022, President Biden directed the Department of Health and Human Services and the DEA to review how marijuana is scheduled under federal law. This review represented a significant policy shift after decades of strict prohibition.
In August 2023, HHS recommended moving marijuana from Schedule I to Schedule III based on scientific and medical evaluation, finding that marijuana has “currently accepted medical use.” The recommendation cited evidence that over six million Americans use cannabis under the guidance of 30,000 healthcare practitioners in medical cannabis programs across the country.
By May 2024, the Department of Justice issued a proposed rule to implement this change. However, the rescheduling process became entangled in administrative hearings and legal challenges. The executive order signed on December 18, 2025, directs the Department of Justice to complete the rulemaking process in the most expeditious manner in accordance with federal law.
What Rescheduling Does Change
The implications of moving cannabis to Schedule III extend across multiple areas, though it’s important to understand both the opportunities and limitations of this policy shift.
Tax Relief for Cannabis Businesses
One of the most immediate impacts will be felt in the financial realm. Currently, cannabis businesses operating legally under state law face a significant tax burden due to Section 280E of the Internal Revenue Code. This provision bars businesses dealing with Schedule I and II substances from claiming standard tax deductions and credits.
If marijuana moves to Schedule III, Section 280E would no longer apply to cannabis businesses, allowing them to deduct ordinary business expenses. For customers at the best dispensary in Washington, this could potentially translate to more competitive pricing as businesses save on their tax obligations.
Expanded Medical Research Opportunities
Rescheduling would significantly reduce barriers to cannabis research. While researchers would still need to obtain materials through DEA-registered manufacturers, a move to Schedule III could broaden the pool of registered suppliers and streamline the registration process.
This improved regulatory environment could facilitate more robust clinical studies on cannabis’s safety and efficacy. Rescheduling would signal to universities and hospitals that cannabis research can be conducted within federal law, addressing concerns that such work jeopardizes federal funding or carries professional stigma.
Reduced Stigma and Recognition of Medical Value
For the first time in almost a century, federal policy would acknowledge that cannabis has legitimate medical applications. This recognition matters beyond symbolism—it could influence how healthcare professionals approach cannabis recommendations and how medical cannabis programs operate in states that don’t yet have them.
At Mary Mart, we’ve long understood what the federal government is now recognizing: cannabis offers valuable therapeutic potential for many people. Our expertly curated selection of flower, concentrates, edibles, and topicals reflects our commitment to quality and variety for both medical and recreational consumers.
What Rescheduling Does NOT Change
While rescheduling represents significant progress, it’s crucial to understand its limitations to avoid misconceptions about what this policy shift actually accomplishes.
Cannabis Remains Federally Illegal for Recreational Use
Moving marijuana to Schedule III does not change the fact that it remains illegal for recreational use at the federal level. The change acknowledges medical value but doesn’t legalize cannabis in the way many people might assume.
State Programs and Prescriptions
Federal FDA approval and a prescription issued by a DEA-registered practitioner would be required for Schedule III substances, yet state medical marijuana programs rely on physician recommendations or certifications rather than valid federal prescriptions. Rescheduling alone doesn’t convert these state-level recommendations into federal prescriptions, nor does it authorize pharmacists to dispense botanical cannabis.
This means that Washington state’s medical and recreational cannabis programs will continue to operate as they currently do. Your visits to the best cannabis dispensary in Pierce County won’t change in terms of how you obtain your products or use your medical card.
Employment and Workplace Testing
Rescheduling would have little to no impact on existing laws that regulate workplace drug testing and safety. Employers can still maintain drug-free workplace policies and test for cannabis use, even in states where it’s legal. The change doesn’t override state-level employment protections, but it also doesn’t create new federal protections for cannabis users.
Banking and Interstate Commerce
While rescheduling may improve some aspects of cannabis business operations, it doesn’t immediately solve all industry challenges. Banking restrictions and interstate commerce barriers would remain in place, though the policy shift could create momentum for addressing these issues through additional legislative action.
What This Means for Washington Cannabis Consumers
Washington state has been at the forefront of cannabis legalization since voters approved recreational use in 2012. Our state’s mature cannabis market already operates with robust regulations and quality standards. So what does federal rescheduling mean for consumers shopping at Mary Mart and other Washington dispensaries?
Continued Access to Quality Products
The most important takeaway is that your access to premium cannabis products won’t be disrupted. Mary Mart will continue offering our full range of products, including:
- Premium flower in indica, sativa, hybrid, and high-CBD strains
- Concentrates including live resin, distillate, hash, and more
- Edibles from trusted brands, with precise dosing
- Vape cartridges and disposables for convenient consumption
- Topicals and tinctures for targeted application
- Pre-rolls both classic and infused
Potential for Better Pricing
As the tax burden on cannabis businesses potentially decreases, some of these savings could be passed on to consumers. While it’s too early to predict exact price changes, the removal of the 280E tax penalty represents a significant cost reduction for dispensaries and cultivators.
At Mary Mart, we’ve always prioritized offering competitive prices across all budgets. Our daily deals and rewards program ensure that quality cannabis remains accessible to our Tacoma community.
Enhanced Product Innovation
With reduced stigma and expanded research opportunities, we may see accelerated development of new cannabis products and delivery methods. The cannabis industry has already shown remarkable innovation within current constraints—imagine what’s possible with fewer barriers to research and development.
Navigating Medical Cannabis in a Changing Landscape
For medical cannabis patients, the rescheduling conversation raises important questions about the future of state medical programs. While the immediate impact may be limited, the long-term trajectory points toward greater integration of cannabis into mainstream healthcare.
Benefits of Maintaining Your Medical Card
Even as the federal landscape shifts, maintaining a medical cannabis authorization in Washington offers tangible benefits. Medical patients at Mary Mart enjoy:
- Higher purchase limits than recreational consumers
- Reduced tax burden on cannabis purchases
- Access to higher-potency products
- Legal protections under Washington state law
We make obtaining your medical card simple with our convenient booking system for consultations with qualified healthcare providers.
Quality and Safety Standards
One aspect that won’t change is the importance of purchasing from licensed, regulated dispensaries. Mary Mart maintains rigorous quality standards, ensuring that every product on our shelves meets Washington state testing requirements. This includes:
- Comprehensive testing for potency and cannabinoid profiles
- Screening for pesticides, heavy metals, and microbial contaminants
- Proper labeling with detailed product information
- Transparent sourcing from trusted cultivators and manufacturers
The Role of State-Level Policies
It’s essential to remember that cannabis legalization in Washington exists independently of federal scheduling. Our state’s regulatory framework will continue to govern how cannabis is grown, tested, sold, and consumed within Washington’s borders.
Washington’s Robust Regulatory System
Washington State’s cannabis program is among the most established in the nation. The Washington State Liquor and Cannabis Board oversees licensing, compliance, and enforcement, ensuring that businesses operate within strict guidelines. This system has created a safe, regulated market that serves both medical patients and recreational consumers.
Continued State Innovation
States like Washington have been laboratories for cannabis policy, developing best practices that could eventually inform federal regulations. As federal attitudes evolve, expect Washington to continue refining its approach to cannabis regulation, possibly expanding access or adjusting policies to reflect new research and consumer needs.
Looking Ahead: The Future of Cannabis Policy
The rescheduling of cannabis represents a milestone, but it’s not the final chapter in cannabis reform. Many advocates view Schedule III as a stepping stone toward more comprehensive changes.
Potential for Further Reform
Some in the cannabis community advocate for complete descheduling—removing cannabis from the controlled substances schedules entirely, similar to alcohol or tobacco. Others push for federal legalization that would create a nationwide framework for cannabis regulation. While these outcomes remain uncertain, the momentum toward reform is undeniable.
Research and Medical Integration
As research barriers diminish, we’ll likely see more clinical studies examining cannabis’s therapeutic applications. This research could lead to FDA-approved cannabis medications, better dosing guidelines, and increased acceptance within the medical community. For patients seeking alternative or complementary therapies, this represents an exciting frontier.
Industry Maturation
The cannabis industry is still relatively young, especially at the federal level. As policies evolve and stigma decreases, expect continued professionalization and standardization. This could mean better product consistency, more sophisticated delivery methods, and enhanced consumer education.
Why Choose Mary Mart as Your Trusted Tacoma Dispensary
At Mary Mart, we’ve built our reputation on providing an exceptional cannabis experience regardless of changing federal policies. Our commitment to our community goes beyond simply selling products—we’re here to educate, support, and serve.
Our Differentiators
What sets Mary Mart apart as the best cannabis source in Pierce County:
- Knowledgeable staff: Our team stays current on industry developments and product information, ready to answer your questions
- Curated selection: We carefully choose products that meet our quality standards
- Welcoming atmosphere: Step into our beautiful dispensary and experience the Mary Mart difference
- Convenient services: Online ordering, medical card bookings, and multiple payment options including contactless Aeropay payments
- Community focus: We’re proud to serve the Tacoma area with competitive pricing and superior service
Visit Us Today
Whether you’re a medical patient, recreational consumer, or someone curious about cannabis, Mary Mart welcomes you. Our location at 3002 6th Ave in Tacoma is open daily from 8am to 11pm, ready to serve you with the premium cannabis products and friendly expertise you deserve.
Browse our online menu to see current inventory, check out our latest deals, or contact us with any questions about products or the rescheduling process.
Frequently Asked Questions
When will cannabis officially be rescheduled to Schedule III?
The timeline remains uncertain. While President Trump’s executive order directs the Department of Justice to complete the rescheduling expeditiously, the administrative process includes hearings and legal review. The process could take several months to finalize.
Will rescheduling make cannabis legal nationwide?
No. Rescheduling to Schedule III acknowledges medical value but doesn’t legalize cannabis for recreational use at the federal level. State laws will continue to govern cannabis access in each jurisdiction.
How will rescheduling affect cannabis prices in Washington?
Reduced tax burdens on cannabis businesses could lead to lower prices over time, though the extent and timing of price changes depend on various market factors. Mary Mart is committed to offering competitive pricing regardless of federal policy changes.
Do I still need a medical card after rescheduling?
Yes. Medical cards provide benefits under Washington state law, including reduced taxes and higher purchase limits. These state-level advantages continue regardless of federal scheduling.
Will rescheduling change how cannabis is tested or regulated in Washington?
No. Washington State’s testing and regulatory requirements operate independently of federal scheduling. You can continue to expect the same quality standards and safety protocols at licensed dispensaries like Mary Mart.
Can employers still test for cannabis use after rescheduling?
Yes. Employment policies regarding drug testing remain largely unchanged by rescheduling. Employers can continue to enforce drug-free workplace policies even in states where cannabis is legal.
Conclusion: Embracing Change While Staying Grounded
The potential rescheduling of cannabis from Schedule I to Schedule III represents a historic acknowledgment of what the cannabis community has known for years: this plant has legitimate medical value and doesn’t belong in the same category as heroin. While this change brings tangible benefits, particularly in research access and business taxation, it’s important to maintain realistic expectations about what rescheduling accomplishes.
For Washington cannabis consumers, life continues much as before. Our state’s mature cannabis program already provides safe, regulated access to quality products. At Mary Mart, your premier Tacoma dispensary, we’ll continue doing what we do best: offering expertly curated products, knowledgeable service, and a welcoming environment for everyone on their cannabis journey.
As federal policy evolves, we’ll keep our community informed about changes that affect your cannabis experience. The path forward may have twists and turns, but the direction is clear: cannabis is increasingly recognized as a legitimate part of wellness and healthcare.
Disclaimer: The information in this article is provided for educational purposes only and does not constitute legal, medical, or professional advice. Cannabis remains illegal under federal law, and state laws vary. Mary Mart does not make medical claims about cannabis products and does not claim that cannabis treats, cures, or prevents any disease or medical condition. Products sold at Mary Mart have not been evaluated or approved by the FDA. Always consult with qualified healthcare and legal professionals regarding your specific situation. Use of cannabis may carry health risks and should be approached responsibly, especially for individuals with underlying health conditions or those taking medications. This information is current as of December 2025 and is subject to change as regulations evolve.
Notes Section (Not for Publication)
Internal Links Used:
- Mary Mart Homepage (https://www.marymart.com/) – Used multiple times to link “Tacoma dispensary,” “best dispensary in Washington,” and related phrases to establish site authority
- Online Menu (https://www.marymart.com/onlinemenu/) – Linked when discussing product selection and inventory
- Deals Page (https://www.marymart.com/deals/) – Referenced when discussing competitive pricing and customer value
- Medical Card Booking (https://medicalmarymart.youcanbook.me) – Linked when discussing medical cannabis benefits
- Contact Page (https://www.marymart.com/contact/) – Provided for reader questions and engagement
External Sources Used:
- Moritz College of Law – Federal Marijuana Rescheduling (https://moritzlaw.osu.edu/faculty-and-research/drug-enforcement-and-policy-center/research-and-grants/policy-and-data-analyses/federal-marijuana-rescheduling) – Educational institution source providing comprehensive timeline and legal analysis of rescheduling process
- Jackson Lewis – Executive Order Analysis (https://www.jacksonlewis.com/insights/potus-orders-doj-complete-rulemaking-process-reschedule-marijuana-expeditiously-three-employer-considerations) – Legal analysis of December 2025 executive order and employment implications
- DEA Drug Scheduling (https://www.dea.gov/drug-information/drug-scheduling) – Official government source (.gov) for controlled substance classifications and examples
- Vicente LLP – Cannabis Rescheduling Explained (https://vicentellp.com/insights/cannabis-rescheduling-explained/) – Cannabis law firm providing detailed analysis of rescheduling implications
- Current Federal Tax Developments – Section 280E Analysis (https://www.currentfederaltaxdevelopments.com/blog/2025/12/19/tax-alert-executive-action-on-marijuana-scheduling-and-the-potential-sunset-of-irc-section-280e) – Professional tax analysis of financial implications
- CBS News – Trump Executive Order (https://www.cbsnews.com/news/trump-order-reclassifying-marijuana-schedule-iii-drug-expected/) – Current news source for recent developments
- Ogletree Deakins – Workplace Impact (https://ogletree.com/insights-resources/blog-posts/president-trump-signs-executive-order-directing-ag-to-expedite-marijuana-rescheduling-process/) – Legal analysis of employment and workplace implications